GSK’s Zejula-Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed on a key secondary endpoint
The high-dose version of Regeneron’s eye treatment Eylea hit its primary endpoint in a late-stage study for macular edema following retinal vein occlusion, a common
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Another trial for SIGA Technologies’ mpox antiviral has failed, and all enrollment has been stopped, the NIH’s National Institute of Allergy and Infectious Diseases announced
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS